Inactivating germline mutations in the BRCA1 gene confer a high risk of developing breast cancer. Although these germline mutations are shown to be rare in the general population (1, 2) , it is thought that a considerable subgroup of breast cancers has characteristics similar to BRCA1 germline mutated breast cancer but without harboring a BRCA1 mutation, so called BRCAness (3) . BRCA1 is important in error-free DNA double strand break (DSB) repair through the homologous recombination pathway (4, 5) . In the absence of functional homologous recombination, DNA repair is mostly performed by error-prone non-homologous end-joining (NHEJ). This in turn leads to genomic instability (6,7). Genomic instability can be measured with DNA copy number profiles. It has been established that DNA copy number (CN) profiles of breast cancers that developed in BRCA1 mutation carriers have a specific signature (8, 9) . To detect these tumors classifiers have been trained that estimate the probability that a copy number profile is similar to a BRCA1 mutated breast cancer ('BRCA1-like') (10) . In addition this classification can also identify tumors that have a defect in BRCA1 due to other causes than mutation, for example hypermethylation of the gene promoter (11, 12) . This means that the biomarker (BRCA1-like signature) captures aspects of the broader concept BRCAness. Preclinical mechanistic studies indicate that deficiencies in this pathway strongly sensitize tumors to drugs inducing DNA damage through DNA double strand breaks, such as platinum compounds and bifunctional alkylators (3, (13) (14) (15) (16) . In general, these drugs are currently not standard therapy in breast cancer. High dose regimens contain such agents. However, in the general population these regimens did not confer a sufficient large survival advantage in the adjuvant or metastatic setting that could Author Manuscript Published OnlineFirst on December 5, 2014; DOI: 10.1158/1078-0432.CCR- justify its toxicity profile. In addition, no known prognostic indicators could identify a subgroup of patients that benefitted substantially from this therapy. Young patients, however seemed to have a better recurrence free survival than older patients (17, 18) .
We therefore investigated in a randomized clinical trial whether patients that classified as BRCA1-like based on their DNA CN profiles, form a subgroup of patients that benefit substantially from DSB inducing high dose (HD) chemotherapy (19) In this study we investigated in an independent single institution cohort whether BRCA1-like patients also benefitted from a tandem HD regimen (22).
Methods

Patients
The patients in this study consist of a cohort of patients that has been treated with adjuvant HD therapy or conventional chemotherapy. High risk breast cancer patients in the HD cohort were enrolled in a single-arm study that was conducted between 1992 and 1997 that evaluated safety and efficacy of the regimen. High risk was defined as 
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Raw image files were processed using Nimblescan software and the DNAcopy algorithm.
Unaveraged DNAcopy files were used as input for the BRCA1-like classifier as previously described (i.e. no training was performed, just application as described) (24). The treatment benefit would be due to decreased systemic disease events, ie. the adjuvant treatment is successful in its aim to kill occult micro-metastases.
Results
We collected the archival material for 82 % of the patients that were treated at the University of Heidelberg. A flow diagram of patients included is shown in Figure 1 .
We generated copy number profiles for 117 of these patients. The clinical characteristics for these patients are shown in Table 1 High dose alkylating regimens in breast cancer are not used anymore after it has been shown that this regimen does not confer a survival benefit (17, 18) . However, these regimens contain potent inducers of DNA double strand breaks which are predicted beneficial in patients with tumors that do not have a functional homologous recombination, due to a defect in BRCA1 (4, (14) (15) (16) 29) . To identify these patients we used a BRCA1-like classifier which assigns patients that share specific DNA copy number aberrations with BRCA1-mutated tumors to the BRCA1-like class (8-10). The tumors assigned to be BRCA1-like comprise BRCA1 mutated and BRCA1 wildtype tumors that have another mechanism to inactivate BRCA1 function, for example BRCA1 promoter hypermethylation (11, 12, 20 
HD regimen carboplatin (1600 mg/m2), thiothepa (480 mg/m2) and cyclophosphamide (6 g/m2) (19). In this study, patients with a BRCA1-like copy number profile in their tumor derived a substantial benefit from another HD regimen compared to conventional chemotherapy. Patients with a non-BRCA1-like tumor that received HD chemotherapy did not benefit at all compared to conventional FEC. Although the HD regimen in the current study (2 cycles induction + 2 cycles of 12 g/m2 ifosfamide, 900 mg/m2 carboplatin and 180 mg/m2 epirubicin) is different from our previous study, we obtained similar results. Our data suggests that patients with a BRCA1-like tumor benefit from an HD alkylating regimen, while patients with a non-BRCA1-like tumor do not.
Given the differences in drugs and doses, it may be that BRCA1-like tumors, generally are more sensitive to the dose or DNA crosslinking properties, rather than a specific agent.
Our present study is limited by several factors, which are shared by other investigations of BRCA1 deficiency as a potential biomarker. In clinical studies there is to date neither agreement on different biomarkers that can be used to identify BRCA1 defects, nor any randomized evidence to demonstrate that selection of patients with a BRCA1 defect for a particular therapy results in improved treatment outcomes as has been reviewed extensively (3, (30) (31) (32) . Clearly our present study is limited by a small sample size and the non-randomized design relying on a balanced patient cohort treated with several chemotherapy combinations during the same time period at the same institution. Regarding the therapy regimens, patients in the control group received conventional chemotherapy consisting of either EC, CMF or EC-CMF as they were treated in the pretaxane era. This allows for a unique view on biology but limits the conclusions on whether HD chemotherapy is better than a modern taxane-containing regimen.
However, it has been suggested that BRCA1 mutated patients are relatively resistant to taxanes (33). Because we do not have an untreated control group it is not possible to accurately model a potential prognostic effect that the BRCA1-like profile status may confer. Secondly, due to the combinations of different drugs, it is impossible to dissect whether the survival benefit could be due to a particular drug. Thirdly, it could also be that the amount of DNA damage is greatly increased due to the higher dose, and that the cumulative dose is responsible for efficient killing of tumor cells. 
Conclusion
Concluding, in this single institution study we observed that BRCA1-like copy number profiles identify a group of patients that recur less often than expected after receiving HD than after conventional chemotherapy treatment. BRCA1-like copy number profile status may therefore be a predictive biomarker for HD alkylating chemotherapy and could then be used to guide treatment choices to improve overall survival among patients with a poor prognosis.
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